Expression of the Immune Checkpoint Regulators LAG-3 and TIM-3 in Classical Hodgkin Lymphoma.
Adult
Aged
Antigens, CD
/ analysis
Antineoplastic Combined Chemotherapy Protocols
/ pharmacology
B7-H1 Antigen
/ analysis
Biopsy
Female
Gene Expression Regulation, Neoplastic
Hepatitis A Virus Cellular Receptor 2
/ analysis
Hodgkin Disease
/ drug therapy
Humans
Immune Checkpoint Inhibitors
/ pharmacology
Male
Middle Aged
Programmed Cell Death 1 Receptor
/ analysis
Reed-Sternberg Cells
/ pathology
Tumor Microenvironment
/ genetics
Young Adult
Lymphocyte Activation Gene 3 Protein
Hodgkin and Reed/Sternberg cells
Immune checkpoints
Immunohistochemistry
Multiplex immunofluorescence
Tumor microenvironment
Journal
Clinical lymphoma, myeloma & leukemia
ISSN: 2152-2669
Titre abrégé: Clin Lymphoma Myeloma Leuk
Pays: United States
ID NLM: 101525386
Informations de publication
Date de publication:
04 2021
04 2021
Historique:
received:
28
09
2020
revised:
03
11
2020
accepted:
07
11
2020
pubmed:
6
12
2020
medline:
11
1
2022
entrez:
5
12
2020
Statut:
ppublish
Résumé
The role of the programmed cell death 1 (PD-1)/programmed death ligand 1 (PD-L1) axis is well established in classical Hodgkin lymphoma (HL), where PD-1 blockade demonstrated spectacular efficacy in relapsed/refractory disease. However, little is known about the frequency and cellular distribution of other immune checkpoints in HL samples. Using immunohistochemistry, we investigated, along with PD-L1 and PD-1, the expression of lymphocyte-activation gene 3 (LAG-3) and T-cell immunoglobulin and mucin-domain containing 3 (TIM-3) in 57 biopsy samples of patients with classical HL. Hodgkin and Reed/Sternberg (HRS) cells were strongly positive for PD-L1 in nearly all cases. HRS cells were TIM-3 positive in 36% of samples, whereas LAG-3 was rarely expressed (5.2%). In the microenvironment, PD-1, LAG-3, and TIM-3 were expressed by ≥ 5% of cells in 65%, 98%, and 96% of cases, respectively. T-cell rosettes surrounding HRS cells consisted of CD4 This study demonstrates for the first time that LAG-3 and TIM-3 are nearly always expressed in the microenvironment of classical HL. This may constitute the basis for targeting LAG-3 or TIM-3 in combination with anti-PD-1 antibodies in the treatment of relapsed/refractory HL.
Identifiants
pubmed: 33277223
pii: S2152-2650(20)30633-9
doi: 10.1016/j.clml.2020.11.009
pii:
doi:
Substances chimiques
Antigens, CD
0
B7-H1 Antigen
0
CD274 protein, human
0
HAVCR2 protein, human
0
Hepatitis A Virus Cellular Receptor 2
0
Immune Checkpoint Inhibitors
0
PDCD1 protein, human
0
Programmed Cell Death 1 Receptor
0
Lymphocyte Activation Gene 3 Protein
0
Lag3 protein, human
0
Banques de données
ClinicalTrials.gov
['NCT02061761', 'NCT03446040']
Types de publication
Journal Article
Observational Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
257-266.e3Informations de copyright
Copyright © 2020 Elsevier Inc. All rights reserved.